Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Shizuka Uchida -- 1546 2022-04-21 18:06:54 |
2 format correct Conner Chen Meta information modification 1546 2022-04-22 02:55:39 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Uchida, S.; Miller, H.; Ilieva, M.; Bishop, A. Epitranscriptomic Marks Affect RNA Structures. Encyclopedia. Available online: https://encyclopedia.pub/entry/22132 (accessed on 03 July 2026).
Uchida S, Miller H, Ilieva M, Bishop A. Epitranscriptomic Marks Affect RNA Structures. Encyclopedia. Available at: https://encyclopedia.pub/entry/22132. Accessed July 03, 2026.
Uchida, Shizuka, Henry Miller, Mirolyuba Ilieva, Alexander Bishop. "Epitranscriptomic Marks Affect RNA Structures" Encyclopedia, https://encyclopedia.pub/entry/22132 (accessed July 03, 2026).
Uchida, S., Miller, H., Ilieva, M., & Bishop, A. (2022, April 21). Epitranscriptomic Marks Affect RNA Structures. In Encyclopedia. https://encyclopedia.pub/entry/22132
Uchida, Shizuka, et al. "Epitranscriptomic Marks Affect RNA Structures." Encyclopedia. Web. 21 April, 2022.
Epitranscriptomic Marks Affect RNA Structures
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ncrna8020023

Long non-coding RNAs (lncRNAs) belong to a class of non-protein-coding RNAs with their lengths longer than 200 nucleotides. Most of the mammalian genome is transcribed as RNA, yet only a small percent of the transcribed RNA corresponds to exons of protein-coding genes. Thus, the number of lncRNAs is predicted to be several times higher than that of protein-coding genes. Because of sheer number of lncRNAs, it is often difficult to elucidate the functions of all lncRNAs, especially those arising from their relationship to their binding partners, such as DNA, RNA, and proteins. Due to their binding to other macromolecules, it has become evident that the structures of lncRNAs influence their functions.

epitranscriptomics gene expression lncRNA

1. Introduction

By definition, long non-coding RNAs (lncRNAs) are any ncRNAs that are longer than 200 nucleotides (nt). With the advancement of high-throughput techniques [microarrays, next generation sequencing (NGS), especially RNA sequencing (RNA-seq)], many lncRNAs have been discovered [1]. To date, a number of functions of lncRNAs have been proposed and experimentally validated; ranging from decoy, epigenetic, transcriptional, post-transcriptional, and translational controls [2][3][4][5]. The general understanding in the field is that lncRNAs exert their actions by binding to other macromolecules, which are DNA, RNA, and proteins [6][7]. Thus, it is essential to identify the potential binding partners to elucidate the mechanism of action of lncRNAs. To this end, the most popular method is using an affinity tag on an in vitro purified RNA and using this RNA as a bait to pull-down proteins/nucleic acids from cellular extracts. There are other more elaborated methods currently available, including ChIRP (Chromatin isolation by RNA purification), CHART (Capture Hybridization Analysis of RNA Targets), CLIP (cross-linking and immunoprecipitation), and RAP (RNA antisense purification), which are comprehensively reviewed elsewhere [8][9][10].
Just as DNA and proteins, RNA can be modified by a variety of enzymes. The classic example is the RNA modifications of ribosomal RNAs (rRNAs) and transfer RNAs (tRNAs), which affect the efficiency of translation [11][12][13]. To date, there are more than 170 RNA modifications known across species [14], which has opened up a new field of study called, epitranscriptomics [15][16], whose name is based on the well-studied field of DNA modification, epigenetics. Much of the concepts of epigenetics are applied to dissect the ever-growing field of epitranscriptomics, including the epitranscriptomic enzymes being categorized as writers, readers, and erasers. Among epitranscriptomic marks, the most well studied one in recent years is N6-methyladenosine (m6A), which is a methylation of nitrogen-6 position of adenosine (A) found in messenger RNAs (mRNAs) and non-protein-coding RNAs (ncRNAs). Other epitranscriptomics marks in mammals include the A-to-I RNA editing, 2′-O-methylation (2′-O-Me), N1-methyladenosine (m1A), 3-methylcytidine (m3C), 5-methylcytosine (m5C), N7-methylguanosine (m7G), pseudouridylation (Ψ) to name a few [17][18]. These epitranscriptomic marks affect all realms of RNA lifecycle, including splicing, subcellular localization, microRNA (miRNA) biogenesis and bindings, RNA stability, and translation efficiency [19][20]. More importantly, dysregulation of epitranscriptomic marks affect many diseases, including cardiovascular [21], liver [22], and neurodegenerative diseases [18] as well as cancers [23].

2. Epitranscriptomic Marks Affect RNA Structures as in the Case of Immune Responses

RNA exists in a single-stranded (ssRNA) or double-stranded RNA (dsRNA) state. The balance between these states may be influenced by cellular conditions, such as stress and viral infection [24][25][26][27]. Furthermore, more than half of the human genome consists of repetitive sequences, such as those derived from transposons and ALU elements [28]. These repetitive sequences form palindromic repeats, resulting in the formation of dsRNAs [29]. To detect dsRNAs, there are several high-throughput methods available, including PARS (Parallel Analysis of RNA Structure) by sequencing RNA digested with RNases S1 and V1 that specifically recognize single-stranded RNA (ssRNAs) and dsRNAs, respectively [30]. Other methods to analyze RNA structures are DMS-Seq to label RNA structures by dimethyl sulfate (DMS) [31], LIGR-seq (LIGation of interacting RNA followed by high-throughput sequencing) to globally map RNA–RNA duplexes crosslinked in vivo [32], PARIS to detect dsRNA [33], RIC-seq (RNA in situ conformation sequencing) to globally profile intra- and intermolecular RNA–RNA interactions [34][35], SHAPE-Seq (selective 2′-hydroxyl acylation analyzed by primer extension sequencing) [36], and SHAPE-MaP (selective 2′-hydroxyl acylation analyzed by primer extension and mutational profiling) to chemically probe RNA by adding RNA-specific small molecules in cell culture [37][38]. Recently, a comprehensive RNA structure probing database, RASP, was released, which contains 18 species (e.g., animals, plants, bacteria, fungi, and viruses) and 18 different experimental methods measuring RNA secondary structures in a transcriptome-wide manner [39]. Furthermore, there are databases for epitranscriptomic marks (comprehensively reviewed in [40]), including RMBase v2.0 [41] and RMVar [42] that contain several epitranscriptomic marks for different organisms. It will be of great interest to further analyze the collected data sets by merging them with high-throughput data that map known epitranscriptomic marks. This will enable the analysis of the preferential distribution of each epitranscriptomic mark to ssRNAs and dsRNAs in different species (thus, evolutional-conservation, if any).
Upon viral infection, the innate immune system is triggered, which recognizes pathogen-associated molecular patterns (PAMPs, which are unique molecular ligands on or within microbes, including viral DNA and RNA) leading to activation of intracellular signaling pathways to initiate antiviral response [43][44]. These PAMPs are detected by the host through pattern recognition receptors, such as Nod-like receptors (NLRs), RIG-I-like receptors (RLRs), and Toll-like receptors (TLRs) [45]. In the case of RLRs, RIG-I senses short dsRNAs, while the RLR, MDA5 (melanoma differentiation-associated protein 5), detects long dsRNAs. These recognitions of PAMPs by RLRs are followed by MAVS (mitochondrial antiviral-signaling protein)-mediated activation of signaling cascades, including type I interferon responses [46][47][48]. The epitranscriptomic mark, m6A, plays active roles in innate immunity by reducing type I interferon production [49][50]. Winkler et al. reported that m6A marks deposited by the m6A METTL3 and read by the m6A reader YTHDF2 negatively regulate interferon response by facilitating the fast turnover of interferon mRNAs leading to viral propagation [49] (Figure 1A). Interestingly, increasing evidence suggests that lncRNAs are shown to be involved in virus infections and antiviral immune responses [51]. Furthermore, many lncRNAs have m6A marks [52][53][54], influencing secondary structures of lncRNAs. For example, MALAT1 (metastasis associated lung adenocarcinoma transcript 1) is involved in inflammatory responses and innate immunity [55][56][57] along with its enzymatic processing product, MALAT1-associated small cytoplasmic RNA (mascRNA) [58][59][60][61][62]. These findings highlight that further investigation of epitranscriptomic marks on lncRNAs and their secondary structural changes may reveal the active involvement of lncRNAs in innate immunity. In this regard, it will be of high interest to understand the relationship between lncRNAs and another epitranscriptomic mark, pseudouridylation (Ψ) [63], as it is demonstrated recently in COVID-19 mRNA vaccines using N1-methylpseudouridine (m1Ψ) to increase their effectiveness [64].
Ncrna 08 00023 g001 550
Figure 1. Epitranscriptomic marks and RNA structures in immune responses. (A) Viral RNA methylation deposited by the m6A writer METTL3 and read by the m6A reader YTHDF2 negatively regulate cellular defense response by facilitating the fast turnover of interferon mRNA leading to viral replication. (B) The role of ADARs in differentiating self-from non-self dsRNA by modulating canonical antiviral pathways induced by dsRNA. During an infection, the viral dsRNA enters into the cytoplasm. Non-edited dsRNA binds to MDA5 (melanoma differentiation-associated protein 5) and RIG-I (retinoic acid-inducible gene I like receptor). This complex activates MAVS (mitochondrial antiviral-signaling protein), leading to the phosphorylation of IRF3 (interferon regulatory transcription factor 3) and its translocation into the nucleus, thus inducing a type 1 interferon response. Endogenous cellular dsRNA that is generated during transcription is A-to-I edited by ADARs. The ADAR1 isoform p150 is cytoplasmic and is induced by interferon. It edits dsRNA either of viral or cellular origin. This dsRNA contains inosine and inhibits the activation of MDA5 and RIG-1, thus turning off the interferon response and apoptosis to prevent autoimmune reaction. However, this mechanism could favor virus replication, if it is not tightly regulated. Figure is created with BioRender.com, accessed on 15 March 2022.
A-to-I RNA editing is a type of epitranscriptomic mark that involves the RNA editing enzymes, ADARs [adenosine deaminases acting on RNA, consisting of three genes: ADAR1, ADARB1 (ADAR2), and catalytically inactive ADARB2 (ADAR3)], recognize dsRNAs to catalyze adenosine to inosine (A-to-I) conversion, mostly at ALU repeats and introns [21]. ALU repeats are ~300 bp that belong to the family of repetitive elements in primates. There are more than one million ALU repeats in primate genomes [65]. Two transcribed ALU repeats form a quasi-palindrome, which becomes double-stranded RNA to recruit ADARs to catalyze A-to-I RNA editing [66]. I is recognized as guanosine (G) by splicing and translational machineries as well as in reverse transcription reactions; allowing detection of A-to-G changes in RNA-seq reads when these reads are mapped to the reference genome [67]. Mutations in the human ADAR1 gene result in the autoimmune disease, Aicardi-Goutières syndrome, while the whole-body knockout mice of Adar1 results in embryonic death due to massive apoptosis and aberrant interferon induction, which can be rescued to live birth by ablating the RLRs, Mavs or Mda5 (melanoma differentiation-associated protein 5) [68][69][70]. Both ADAR1 and ADAR2 are important in differentiating self- from non-self dsRNAs [69][71][72] (Figure 1B). Furthermore, silencing of ADAR1 in the human hepatocellular carcinoma cell line, HepG2, resulted in shifting of dsRNAs to ssRNAs at the transcriptome-wide level [73]. As many lncRNAs have A-to-I RNA editing sites [74][75], further characterization of RNA editing sites will uncover the secondary structures of lncRNAs, especially the conversion of A to I at the nitrogen-6 position of adenosine, which can be methylated as m6A, if not edited [76]. Thus, both epitranscriptomic marks, A-to-I RNA editing and m6A, could competitively affect the secondary structures of lncRNAs, thereby, influencing the binding of other macromolecules.

References

  1. Seal, R.L.; Chen, L.L.; Griffiths-Jones, S.; Lowe, T.M.; Mathews, M.B.; O’Reilly, D.; Pierce, A.J.; Stadler, P.F.; Ulitsky, I.; Wolin, S.L.; et al. A guide to naming human non-coding RNA genes. EMBO J. 2020, 39, e103777.
  2. Andergassen, D.; Rinn, J.L. From genotype to phenotype: Genetics of mammalian long non-coding RNAs in vivo. Nat. Rev. Genet. 2021, 23, 229–243.
  3. Rinn, J.L.; Chang, H.Y. Long Noncoding RNAs: Molecular Modalities to Organismal Functions. Annu. Rev. Biochem. 2020, 89, 283–308.
  4. Moore IV, J.B.; Uchida, S. Functional characterization of long noncoding RNAs. Curr. Opin. Cardiol. 2020, 35, 199–206.
  5. Yao, R.W.; Wang, Y.; Chen, L.L. Cellular functions of long noncoding RNAs. Nat. Cell Biol. 2019, 21, 542–551.
  6. Garikipati, V.N.S.; Uchida, S. Elucidating the Functions of Non-Coding RNAs from the Perspective of RNA Modifications. Noncoding RNA 2021, 7, 31.
  7. Statello, L.; Guo, C.J.; Chen, L.L.; Huarte, M. Gene regulation by long non-coding RNAs and its biological functions. Nat. Rev. Mol. Cell Biol. 2021, 22, 96–118.
  8. Cao, M.; Zhao, J.; Hu, G. Genome-wide methods for investigating long noncoding RNAs. Biomed. Pharm. 2019, 111, 395–401.
  9. Hafner, M.; Katsantoni, M.; Köster, T.; Marks, J.; Mukherjee, J.; Staiger, D.; Ule, J.; Zavolan, M. CLIP and complementary methods. Nat. Rev. Methods Primers 2021, 1, 20.
  10. Ramanathan, M.; Porter, D.F.; Khavari, P.A. Methods to study RNA-protein interactions. Nat. Methods 2019, 16, 225–234.
  11. Ranjan, N.; Leidel, S.A. The epitranscriptome in translation regulation: mRNA and tRNA modifications as the two sides of the same coin? FEBS Lett. 2019, 593, 1483–1493.
  12. Bastide, A.; David, A. Interaction of rRNA with mRNA and tRNA in Translating Mammalian Ribosome: Functional Implications in Health and Disease. Biomolecules 2018, 8, 100.
  13. Lyons, S.M.; Fay, M.M.; Ivanov, P. The role of RNA modifications in the regulation of tRNA cleavage. FEBS Lett. 2018, 592, 2828–2844.
  14. Boccaletto, P.; Machnicka, M.A.; Purta, E.; Piatkowski, P.; Baginski, B.; Wirecki, T.K.; de Crecy-Lagard, V.; Ross, R.; Limbach, P.A.; Kotter, A.; et al. MODOMICS: A database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018, 46, D303–D307.
  15. Roundtree, I.A.; He, C. RNA epigenetics-chemical messages for posttranscriptional gene regulation. Curr. Opin. Chem. Biol. 2016, 30, 46–51.
  16. Saletore, Y.; Meyer, K.; Korlach, J.; Vilfan, I.D.; Jaffrey, S.; Mason, C.E. The birth of the Epitranscriptome: Deciphering the function of RNA modifications. Genome Biol. 2012, 13, 175.
  17. Wiener, D.; Schwartz, S. The epitranscriptome beyond m(6)A. Nat. Rev. Genet. 2021, 22, 119–131.
  18. Angelova, M.T.; Dimitrova, D.G.; Dinges, N.; Lence, T.; Worpenberg, L.; Carre, C.; Roignant, J.Y. The Emerging Field of Epitranscriptomics in Neurodevelopmental and Neuronal Disorders. Front. Bioeng. Biotechnol. 2018, 6, 46.
  19. Kumar, S.; Mohapatra, T. Deciphering Epitranscriptome: Modification of mRNA Bases Provides a New Perspective for Post-transcriptional Regulation of Gene Expression. Front. Cell Dev. Biol. 2021, 9, 628415.
  20. Li, S.; Mason, C.E. The pivotal regulatory landscape of RNA modifications. Annu. Rev. Genom. Hum. Genet. 2014, 15, 127–150.
  21. Uchida, S.; Jones, S.P. RNA Editing: Unexplored Opportunities in the Cardiovascular System. Circ. Res. 2018, 122, 399–401.
  22. Zhao, Z.; Meng, J.; Su, R.; Zhang, J.; Chen, J.; Ma, X.; Xia, Q. Epitranscriptomics in liver disease: Basic concepts and therapeutic potential. J. Hepatol. 2020, 73, 664–679.
  23. Lian, H.; Wang, Q.H.; Zhu, C.B.; Ma, J.; Jin, W.L. Deciphering the Epitranscriptome in Cancer. Trends Cancer 2018, 4, 207–221.
  24. Reineke, L.C.; Kedersha, N.; Langereis, M.A.; van Kuppeveld, F.J.; Lloyd, R.E. Stress granules regulate double-stranded RNA-dependent protein kinase activation through a complex containing G3BP1 and Caprin1. mBio 2015, 6, e02486.
  25. Dabo, S.; Meurs, E.F. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012, 4, 2598–2635.
  26. Mertens, P. The dsRNA viruses. Virus Res. 2004, 101, 3–13.
  27. Sadeq, S.; Al-Hashimi, S.; Cusack, C.M.; Werner, A. Endogenous Double-Stranded RNA. Noncoding RNA 2021, 7, 15.
  28. Lander, E.S.; Linton, L.M.; Birren, B.; Nusbaum, C.; Zody, M.C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; et al. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860–921.
  29. Trigiante, G.; Blanes Ruiz, N.; Cerase, A. Emerging Roles of Repetitive and Repeat-Containing RNA in Nuclear and Chromatin Organization and Gene Expression. Front. Cell Dev. Biol. 2021, 9, 735527.
  30. Kertesz, M.; Wan, Y.; Mazor, E.; Rinn, J.L.; Nutter, R.C.; Chang, H.Y.; Segal, E. Genome-wide measurement of RNA secondary structure in yeast. Nature 2010, 467, 103–107.
  31. Rouskin, S.; Zubradt, M.; Washietl, S.; Kellis, M.; Weissman, J.S. Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo. Nature 2014, 505, 701–705.
  32. Sharma, E.; Sterne-Weiler, T.; O’Hanlon, D.; Blencowe, B.J. Global Mapping of Human RNA-RNA Interactions. Mol. Cell 2016, 62, 618–626.
  33. Lu, Z.; Gong, J.; Zhang, Q.C. PARIS: Psoralen Analysis of RNA Interactions and Structures with High Throughput and Resolution. Methods Mol. Biol. 2018, 1649, 59–84.
  34. Cao, C.; Cai, Z.; Ye, R.; Su, R.; Hu, N.; Zhao, H.; Xue, Y. Global in situ profiling of RNA-RNA spatial interactions with RIC-seq. Nat. Protoc. 2021, 16, 2916–2946.
  35. Cai, Z.; Cao, C.; Ji, L.; Ye, R.; Wang, D.; Xia, C.; Wang, S.; Du, Z.; Hu, N.; Yu, X.; et al. RIC-seq for global in situ profiling of RNA-RNA spatial interactions. Nature 2020, 582, 432–437.
  36. Lucks, J.B.; Mortimer, S.A.; Trapnell, C.; Luo, S.; Aviran, S.; Schroth, G.P.; Pachter, L.; Doudna, J.A.; Arkin, A.P. Multiplexed RNA structure characterization with selective 2′-hydroxyl acylation analyzed by primer extension sequencing (SHAPE-Seq). Proc. Natl. Acad. Sci. USA 2011, 108, 11063–11068.
  37. Smola, M.J.; Weeks, K.M. In-cell RNA structure probing with SHAPE-MaP. Nat. Protoc. 2018, 13, 1181–1195.
  38. Smola, M.J.; Rice, G.M.; Busan, S.; Siegfried, N.A.; Weeks, K.M. Selective 2′-hydroxyl acylation analyzed by primer extension and mutational profiling (SHAPE-MaP) for direct, versatile and accurate RNA structure analysis. Nat. Protoc. 2015, 10, 1643–1669.
  39. Li, P.; Zhou, X.; Xu, K.; Zhang, Q.C. RASP: An atlas of transcriptome-wide RNA secondary structure probing data. Nucleic Acids Res. 2021, 49, D183–D191.
  40. Ma, J.; Zhang, L.; Chen, S.; Liu, H. A brief review of RNA modification related database resources. Methods 2021, 21, S1046-2023.
  41. Xuan, J.J.; Sun, W.J.; Lin, P.H.; Zhou, K.R.; Liu, S.; Zheng, L.L.; Qu, L.H.; Yang, J.H. RMBase v2.0: Deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res. 2018, 46, D327–D334.
  42. Luo, X.; Li, H.; Liang, J.; Zhao, Q.; Xie, Y.; Ren, J.; Zuo, Z. RMVar: An updated database of functional variants involved in RNA modifications. Nucleic Acids Res. 2021, 49, D1405–D1412.
  43. Ren, Z.; Ding, T.; Zuo, Z.; Xu, Z.; Deng, J.; Wei, Z. Regulation of MAVS Expression and Signaling Function in the Antiviral Innate Immune Response. Front. Immunol. 2020, 11, 1030.
  44. Chintakuntlawar, A.V.; Zhou, X.; Rajaiya, J.; Chodosh, J. Viral capsid is a pathogen-associated molecular pattern in adenovirus keratitis. PLoS Pathog. 2010, 6, e1000841.
  45. Thompson, M.R.; Kaminski, J.J.; Kurt-Jones, E.A.; Fitzgerald, K.A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011, 3, 920–940.
  46. Kimura, S.; Matsumiya, T.; Shiba, Y.; Nakanishi, M.; Hayakari, R.; Kawaguchi, S.; Yoshida, H.; Imaizumi, T. The Essential Role of Double-Stranded RNA-Dependent Antiviral Signaling in the Degradation of Nonself Single-Stranded RNA in Nonimmune Cells. J. Immunol. 2018, 201, 1044–1052.
  47. Okamoto, M.; Tsukamoto, H.; Kouwaki, T.; Seya, T.; Oshiumi, H. Recognition of Viral RNA by Pattern Recognition Receptors in the Induction of Innate Immunity and Excessive Inflammation During Respiratory Viral Infections. Viral Immunol. 2017, 30, 408–420.
  48. Saito, T.; Gale, M., Jr. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med. 2008, 205, 1523–1527.
  49. Winkler, R.; Gillis, E.; Lasman, L.; Safra, M.; Geula, S.; Soyris, C.; Nachshon, A.; Tai-Schmiedel, J.; Friedman, N.; Le-Trilling, V.T.K.; et al. m(6)A modification controls the innate immune response to infection by targeting type I interferons. Nat. Immunol. 2019, 20, 173–182.
  50. Rubio, R.M.; Depledge, D.P.; Bianco, C.; Thompson, L.; Mohr, I. RNA m(6) A modification enzymes shape innate responses to DNA by regulating interferon beta. Genes Dev. 2018, 32, 1472–1484.
  51. Qiu, L.; Wang, T.; Tang, Q.; Li, G.; Wu, P.; Chen, K. Long Non-coding RNAs: Regulators of Viral Infection and the Interferon Antiviral Response. Front. Microbiol. 2018, 9, 1621.
  52. Liu, N.; Parisien, M.; Dai, Q.; Zheng, G.; He, C.; Pan, T. Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. RNA 2013, 19, 1848–1856.
  53. Meyer, K.D.; Saletore, Y.; Zumbo, P.; Elemento, O.; Mason, C.E.; Jaffrey, S.R. Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell 2012, 149, 1635–1646.
  54. Dominissini, D.; Moshitch-Moshkovitz, S.; Schwartz, S.; Salmon-Divon, M.; Ungar, L.; Osenberg, S.; Cesarkas, K.; Jacob-Hirsch, J.; Amariglio, N.; Kupiec, M.; et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 2012, 485, 201–206.
  55. Wang, M.C.; McCown, P.J.; Schiefelbein, G.E.; Brown, J.A. Secondary Structural Model of MALAT1 Becomes Unstructured in Chronic Myeloid Leukemia and Undergoes Structural Rearrangement in Cervical Cancer. Noncoding RNA 2021, 7, 6.
  56. McCown, P.J.; Wang, M.C.; Jaeger, L.; Brown, J.A. Secondary Structural Model of Human MALAT1 Reveals Multiple Structure-Function Relationships. Int. J. Mol. Sci. 2019, 20, 5610.
  57. Zhou, K.I.; Parisien, M.; Dai, Q.; Liu, N.; Diatchenko, L.; Sachleben, J.R.; Pan, T. N(6)-Methyladenosine Modification in a Long Noncoding RNA Hairpin Predisposes Its Conformation to Protein Binding. J. Mol. Biol. 2016, 428, 822–833.
  58. Sun, T.; Wei, C.; Wang, D.; Wang, X.; Wang, J.; Hu, Y.; Mao, X. The small RNA mascRNA differentially regulates TLR-induced proinflammatory and antiviral responses. JCI Insight 2021, 6, e150833.
  59. Liu, W.; Wang, Z.; Liu, L.; Yang, Z.; Liu, S.; Ma, Z.; Liu, Y.; Ma, Y.; Zhang, L.; Zhang, X.; et al. LncRNA Malat1 inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. Proc. Natl. Acad. Sci. USA 2020, 117, 23695–23706.
  60. Feng, L.L.; Xin, W.N.; Tian, X.L. MALAT1 modulates miR-146′s protection of microvascular endothelial cells against LPS-induced NF-kappaB activation and inflammatory injury. Innate Immun. 2019, 25, 433–443.
  61. Gast, M.; Rauch, B.H.; Nakagawa, S.; Haghikia, A.; Jasina, A.; Haas, J.; Nath, N.; Jensen, L.; Stroux, A.; Bohm, A.; et al. Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE-/-mice. Cardiovasc. Res. 2019, 115, 302–314.
  62. Gast, M.; Schroen, B.; Voigt, A.; Haas, J.; Kuehl, U.; Lassner, D.; Skurk, C.; Escher, F.; Wang, X.; Kratzer, A.; et al. Long noncoding RNA MALAT1-derived mascRNA is involved in cardiovascular innate immunity. J. Mol. Cell Biol. 2016, 8, 178–181.
  63. Zhang, W.; Eckwahl, M.J.; Zhou, K.I.; Pan, T. Sensitive and quantitative probing of pseudouridine modification in mRNA and long noncoding RNA. RNA 2019, 25, 1218–1225.
  64. Nance, K.D.; Meier, J.L. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent. Sci. 2021, 7, 748–756.
  65. Batzer, M.A.; Deininger, P.L. Alu repeats and human genomic diversity. Nat. Rev. Genet. 2002, 3, 370–379.
  66. Fumagalli, D.; Gacquer, D.; Rothe, F.; Lefort, A.; Libert, F.; Brown, D.; Kheddoumi, N.; Shlien, A.; Konopka, T.; Salgado, R.; et al. Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. Cell Rep. 2015, 13, 277–289.
  67. John, D.; Weirick, T.; Dimmeler, S.; Uchida, S. RNAEditor: Easy detection of RNA editing events and the introduction of editing islands. Brief. Bioinform. 2017, 18, 993–1001.
  68. Pestal, K.; Funk, C.C.; Snyder, J.M.; Price, N.D.; Treuting, P.M.; Stetson, D.B. Isoforms of RNA-Editing Enzyme ADAR1 Independently Control Nucleic Acid Sensor MDA5-Driven Autoimmunity and Multi-organ Development. Immunity 2015, 43, 933–944.
  69. Liddicoat, B.J.; Piskol, R.; Chalk, A.M.; Ramaswami, G.; Higuchi, M.; Hartner, J.C.; Li, J.B.; Seeburg, P.H.; Walkley, C.R. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 2015, 349, 1115–1120.
  70. Mannion, N.M.; Greenwood, S.M.; Young, R.; Cox, S.; Brindle, J.; Read, D.; Nellaker, C.; Vesely, C.; Ponting, C.P.; McLaughlin, P.J.; et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014, 9, 1482–1494.
  71. Yanai, M.; Kojima, S.; Sakai, M.; Komorizono, R.; Tomonaga, K.; Makino, A. ADAR2 Is Involved in Self and Nonself Recognition of Borna Disease Virus Genomic RNA in the Nucleus. J. Virol. 2020, 94, e01513–e01519.
  72. Pujantell, M.; Riveira-Munoz, E.; Badia, R.; Castellvi, M.; Garcia-Vidal, E.; Sirera, G.; Puig, T.; Ramirez, C.; Clotet, B.; Este, J.A.; et al. RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages. Sci. Rep. 2017, 7, 13339.
  73. Solomon, O.; Di Segni, A.; Cesarkas, K.; Porath, H.T.; Marcu-Malina, V.; Mizrahi, O.; Stern-Ginossar, N.; Kol, N.; Farage-Barhom, S.; Glick-Saar, E.; et al. RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure. Nat. Commun. 2017, 8, 1440.
  74. Porath, H.T.; Knisbacher, B.A.; Eisenberg, E.; Levanon, E.Y. Massive A-to-I RNA editing is common across the Metazoa and correlates with dsRNA abundance. Genome Biol. 2017, 18, 185.
  75. Galipon, J.; Ishii, R.; Suzuki, Y.; Tomita, M.; Ui-Tei, K. Differential Binding of Three Major Human ADAR Isoforms to Coding and Long Non-Coding Transcripts. Genes 2017, 8, 68.
  76. Xiang, J.F.; Yang, Q.; Liu, C.X.; Wu, M.; Chen, L.L.; Yang, L. N(6)-Methyladenosines Modulate A-to-I RNA Editing. Mol. Cell 2018, 69, 126–135.e6.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biochemistry & Molecular Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Shizuka Uchida , Henry Miller , Mirolyuba Ilieva , Alexander Bishop
View Times: 615
Revisions: 2 times (View History)
Update Date: 22 Apr 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback